- Qiagen expands its liquid biopsy portfolio, enhancing oncology, prenatal care, and organ transplant applications with new kits and updates to the EZ2 Connect platform.
- The upgrades include a new urine protocol for the EZ1&2 ccfDNA Kit and new QIAsymphony DSP Circulating DNA Kits, supporting larger sample volumes and improving workflows for cancer research.
- These advancements reinforce QIAGEN’s leadership in non-invasive diagnostic solutions.
Thu Oct 10 21:10:08 -0000 2024 UTC– QIAGEN has expanded its liquid biopsy solutions for oncology, prenatal care, and organ transplant applications, reinforcing their leadership in automated solutions for non-invasive liquid biopsies.
Updates include a new ccfDNA Kit with a urine protocol for EZ1 and 2 instruments, QIAsymphony DSP Circulating DNA Kits for high-quality cfDNA, and complete automated solutions for ccfDNA isolation supporting various sample volumes and technologies.
These enhancements aim to improve efficiency and accuracy in oncology research and diagnostics.